Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adeno-associated virus-mediated survivin mutant Thr34Ala cooperates with oxaliplatin to inhibit tumor growth and angiogenesis in colon cancer.

Oncology reports - 1 Apr 2011

Xue Zhimou, Sun Ping Hu, Zhu Li Ming, Jiang Shi Hu, Qiao Min Min, Chi Alfred L, Tu Shui Ping

Abstract excerpt

Colon cancer is one of the most common cancers. Survivin is overexpressed in human colon cancer and correlate with chemoresistance, angiogenesis and poor prognosis. Oxaliplatin, a platinum derivative cancer drug, has been used for treating human colorectal cancers. In the present study, we investigated the effect of the adeno-associated virus (AAV)-mediated survivin mutant Thr34Ala [rAAV-Sur-Mut(T34A)] on colon...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dependovirus
Share to Immunoenzyme Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitor of Apoptosis Proteins

Share to Neovascularization, Pathologic

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Survivin

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 21279308
DOI: 10.3892/or.2011.1166

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adeno-associated virus-mediated survivin mutant Thr34Ala cooperates with oxaliplatin to inhibit tumor growth and angiogenesis in colon cancer.PMID 21279308Read ↗

Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanismsSemantic proximity Read ↗

Enhancement of oxaliplatin-induced cell apoptosis and tumor suppression by 3-methyladenine in colon cancerSemantic proximity Read ↗

Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer.Semantic proximity Read ↗

Newcastle Disease Virus Expressing an Angiogenic Inhibitor Exerts an Enhanced Therapeutic Efficacy in Colon Cancer ModelSemantic proximity Read ↗

A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylationSemantic proximity Read ↗

A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.Semantic proximity Read ↗

Mutation detection in the promoter region of survivin gene on N-methyl-N-nitrosourea induced colon tumor model in experiment.Semantic proximity Read ↗

Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.Semantic proximity Read ↗

Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS.Semantic proximity Read ↗

Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival.Semantic proximity Read ↗

MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo.Semantic proximity Read ↗

Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.